Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
albinterferon alfa-2b + ribavirin
- Development stage
- Unknown
- Lead developer
- GSK
- Modality
- Small Molecules, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Administration
- Subcutaneous, Oral
01
Overview
Albinterferon alfa-2b + ribavirin is a combination therapy studied primarily for the treatment of chronic hepatitis C virus (HCV) infection. Albinterferon alfa-2b (Albuferon) is a recombinant fusion protein of human albumin and interferon alfa-2b, designed to have a longer half-life than conventional interferon, allowing for less frequent dosing. Ribavirin is a synthetic guanosine analog with broad-spectrum antiviral activity, used as an adjunct to interferon-based therapies for HCV. The mechanism involves immune modulation and inhibition of viral replication: albinterferon stimulates immune response through interferon signaling pathways, while ribavirin acts by multiple mechanisms including inhibition of viral RNA synthesis. The combination was developed and clinically evaluated by Human Genome Sciences and Novartis for use as an alternative to standard pegylated interferon plus ribavirin regimens in chronic hepatitis C, aiming to improve efficacy and tolerability[5][6][7].
- Brand names
- Albuferon + ribavirin
- Other names
- albinterferon alpha-2b + ribavirinalbIFN alfa-2b + ribavirinHuman albumin-interferon alpha-2b fusion protein + ribavirin
02
Targets
IFNAR (Immune system modulation via type I interferon receptor)IMPDH (Inosine-5'-monophosphate dehydrogenase 1)RdRp (Coronavirus RNA-dependent RNA polymerase)
Beyond the preview
Go deeper on albinterferon alfa-2b + ribavirin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on albinterferon alfa-2b + ribavirin.